Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) produced a 51.78% rally since recording the worst price of $4.5. Thanks to the latest 4.75% increase, it now trades at $6.83. Throughout the trading on 3/14/2019, the share price floated between $6.4525 and $7. This company shares are 256.22% off its target price of $24.33 and the current market capitalization stands at $430.77M. The recent change has given its price a -7.49% deficit over SMA 50 and -25.03% deficit over its 52-week high. The stock witnessed -20.3% declines, -1.01% declines and 26.48% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found CRBP’s volatility during a week at 10.05% and during a month it has been found around 8.68%.Corbus Pharmaceuticals Holdings, Inc. (CRBP) Top Holders
Institutional investors currently hold around $169 million or 41.9% in CRBP stock. Look at its top three institutional owners: Blackrock Inc. owns $33.51 million in Corbus Pharmaceuticals Holdings, Inc., which represents roughly 7.78% of the company’s market cap and approximately 19.83% of the institutional ownership. Similar statistics are true for the second largest owner, Knoll Capital Management, Lp, which owns 4,062,791 shares of the stock are valued at $26.49 million. The third largest holder is Etf Managers Group, Llc, which currently holds $25.81 million worth of this stock and that ownership represents nearly 5.99% of its market capitalization.Corbus Pharmaceuticals Holdings, Inc. 13F Filings
At the end of December reporting period, 45 institutional holders increased their position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) by some 5,600,030 shares, 30 decreased positions by 1,703,211 and 15 held positions by 18,626,295. That puts total institutional holdings at 25,929,536 shares, according to SEC filings. The stock grabbed 14 new institutional investments totaling 4,775,047 shares while 7 institutional investors sold out their entire positions totaling 385,919 shares.Corbus Pharmaceuticals Holdings, Inc. (CRBP) Analyst Guide
Several analysts have released their opinion on Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), with 0 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 8 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation [T1].